Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ott

Showing results (231-240 of 237) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 237 results.
Molecular Cancer Therapeutics|November 19, 2024
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628Darwin A Garcia, Sneha Rathi, Margaret A Connors, et al.
Exploration of Targeted Anti-Tumor Therapy|December 8, 2025
Optimizing procedures for ocular radiation injury studies in the tree shrewLauren A Dalvin, Kjersten J Anderson, Tommy A Rinkoski, et al.
Neuro-Oncology Advances|February 10, 2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenograftsRachael A Vaubel, Wenjuan Zhang, Nishika Karbhari, et al.
Neuro-Oncology|April 15, 2025
The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenograftsZhiyi Xue, Ann C Mladek, Sneha Rathi, et al.
Molecular Cancer Therapeutics|October 23, 2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway DeficitsSonja Dragojevic, Emily J Smith, Michael S Regan, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
A MET-Targeted Variable New Antigen Receptor (VNAR) Theranostic for Non-Small Cell Lung CancerRachel L Minne, Jayden L West, Natalie Y Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type GlioblastomaRachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Pageof 24

Showing results (231-240 of 237) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 237 results.
Molecular Cancer Therapeutics|November 19, 2024
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628Darwin A Garcia, Sneha Rathi, Margaret A Connors, et al.
Exploration of Targeted Anti-Tumor Therapy|December 8, 2025
Optimizing procedures for ocular radiation injury studies in the tree shrewLauren A Dalvin, Kjersten J Anderson, Tommy A Rinkoski, et al.
Neuro-Oncology Advances|February 10, 2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenograftsRachael A Vaubel, Wenjuan Zhang, Nishika Karbhari, et al.
Neuro-Oncology|April 15, 2025
The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenograftsZhiyi Xue, Ann C Mladek, Sneha Rathi, et al.
Molecular Cancer Therapeutics|October 23, 2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway DeficitsSonja Dragojevic, Emily J Smith, Michael S Regan, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
A MET-Targeted Variable New Antigen Receptor (VNAR) Theranostic for Non-Small Cell Lung CancerRachel L Minne, Jayden L West, Natalie Y Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type GlioblastomaRachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Pageof 24